DRIO vs. CTCX, XAIR, GBS, APYX, NSPR, DXR, CTSO, LNSR, CODX, and LUCD
Should you be buying DarioHealth stock or one of its competitors? The main competitors of DarioHealth include Carmell (CTCX), Beyond Air (XAIR), GBS (GBS), Apyx Medical (APYX), InspireMD (NSPR), Daxor (DXR), Cytosorbents (CTSO), LENSAR (LNSR), Co-Diagnostics (CODX), and Lucid Diagnostics (LUCD). These companies are all part of the "surgical & medical instruments" industry.
DarioHealth (NASDAQ:DRIO) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
DarioHealth received 238 more outperform votes than Carmell when rated by MarketBeat users.
In the previous week, DarioHealth had 1 more articles in the media than Carmell. MarketBeat recorded 1 mentions for DarioHealth and 0 mentions for Carmell. Carmell's average media sentiment score of 0.98 beat DarioHealth's score of 0.67 indicating that Carmell is being referred to more favorably in the news media.
Carmell has a net margin of 0.00% compared to DarioHealth's net margin of -165.96%. DarioHealth's return on equity of -48.84% beat Carmell's return on equity.
Carmell has lower revenue, but higher earnings than DarioHealth.
33.4% of DarioHealth shares are held by institutional investors. Comparatively, 24.2% of Carmell shares are held by institutional investors. 10.1% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
DarioHealth presently has a consensus target price of $5.37, suggesting a potential upside of 241.83%. Given DarioHealth's higher probable upside, equities analysts plainly believe DarioHealth is more favorable than Carmell.
DarioHealth has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.
Summary
DarioHealth beats Carmell on 9 of the 13 factors compared between the two stocks.
Get DarioHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DarioHealth Competitors List
Related Companies and Tools
